Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. I
- PMID: 1761118
- DOI: 10.1111/j.1600-0609.1991.tb01856.x
Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. I
Abstract
All patients in the region with newly discovered M components were registered from 15 Aug. 1984-31 Dec. 1986. Among a total of 393 patients enrolled, 162 had multiple myeloma (MM). The incidence rate was 6.6 per 100,000 population per year (age-adjusted to the European standard population), which is somewhat higher than previous reports based on hospital and autopsy records. In particular, the incidence rate was higher in the greater than 70 age group. Thus, the median age was 72 yr, which is the highest reported. As many as 71 (44%) of the 162 MM patients were asymptomatic; these asymptomatic patients had the same age distribution as the symptomatic ones. The stage distribution, occurrence of risk factors, response to chemotherapy, response duration and survival were similar in the age groups below and above the median and, in multivariate survival analysis, age was not an independent risk factor.
Similar articles
-
Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway. II.Eur J Haematol. 1991 Nov;47(5):338-41. doi: 10.1111/j.1600-0609.1991.tb01857.x. Eur J Haematol. 1991. PMID: 1761119
-
Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.Haematologica. 2018 Mar;103(3):506-513. doi: 10.3324/haematol.2017.178103. Epub 2017 Dec 7. Haematologica. 2018. PMID: 29217784 Free PMC article.
-
A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK.Br J Haematol. 2004 Nov;127(3):299-304. doi: 10.1111/j.1365-2141.2004.05207.x. Br J Haematol. 2004. PMID: 15491289
-
Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2018;47(4):203-211. doi: 10.17849/insm-47-04-1-9.1. Epub 2019 Jan 22. J Insur Med. 2018. PMID: 30668210
-
The incidence and epidemiology of plasma cell neoplasms.Stem Cells. 1995 Aug;13 Suppl 2:1-9. Stem Cells. 1995. PMID: 8520495 Review.
Cited by
-
Targeted treatments for multiple myeloma: specific role of carfilzomib.Pharmgenomics Pers Med. 2015 Jan 20;8:23-33. doi: 10.2147/PGPM.S39085. eCollection 2015. Pharmgenomics Pers Med. 2015. PMID: 25691814 Free PMC article. Review.
-
More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis.Drug Des Devel Ther. 2016 Nov 8;10:3673-3679. doi: 10.2147/DDDT.S100062. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27877018 Free PMC article.
-
Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.Pharmacoeconomics. 1999 Oct;16(4):329-41. doi: 10.2165/00019053-199916040-00002. Pharmacoeconomics. 1999. PMID: 10623362 Review.
-
Epidemiology of the M-component immunoglobulin types of multiple myeloma.Cancer Causes Control. 1993 Mar;4(2):83-92. doi: 10.1007/BF00053148. Cancer Causes Control. 1993. PMID: 8481497
-
Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.Pharmacoeconomics. 1997 Jul;12(1):89-103. doi: 10.2165/00019053-199712010-00009. Pharmacoeconomics. 1997. PMID: 10169390 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials